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INTRODUCTION
The major goals of this project were the establishment of a telemedicine system for comprehensive diabetes management and the assessment of diabetic retinopathy that a) provides increased access for diabetic patients to appropriate care, b) centralizes the patients in the care process, c) empowers the patient to better manage their disease, d) can be performed in a cost effective manner, and e) maintains the high standard of care required for the appropriate management of diabetic patients.
As part of this program we performed appropriate clinical validation, cost efficiency, and risk benefit studies associated with the use of the Comprehensive Diabetes Management Program (CDMP) and the Joslin Vision Network (JVN) Eye Health Care Program that is now a module of the CDMP. The work performed here also had a secondary focus of continuing the ongoing research associated with the development of new modules for the CDMP, and the development and validation of computer algorithms designed to automate detection of retinal lesions developed during the course of retinopathy development and automate decision support associated with appropriate follow up eye care.
The need for diabetes disease management is driven by the knowledge that diabetes is not currently curable; but it is treatable and its complications are preventable through optimal care-and self-management. However, the traditional physician-centered, episodic, acute-care model is not designed to optimize care-and selfmanagement, especially with large numbers of diabetic patients (2, 200 new cases diagnosed every day in the US). To do requires that the health care delivery system be re-engineered. Such re-engineering is a reality with the use of the CDMP developed under this collaborative effort.
Summary Status Report for Clinical Research Projects
The following describes the purpose and methods of the 6 clinical and observational studies associated with this project, and then gives a status report for each.
tele-retinal imaging exam in screening patients with diabetes for eye diseases in distinction to prior modeled analyses.
3. Human Factors study of the CDMP: Usability Lab. This study followed an Expert Review (see Table 1 ) of the CDMP, conducted by the American Institutes for Research and funded separately. The purpose of this study was to conduct a usability test of the CDMP under controlled laboratory conditions. In brief, the CDMP is an Internet-based Informatics tool that has numerous functions for facilitating and improving care and tracking of patients with diabetes. We were interested in learning whether the CDMP is "user-friendly" and compatible with diabetes care providers' normal workflow. The study design involved recruiting diabetes care providers (N = 6) and asking them to use the CDMP to perform tasks simulating actual patient encounters in the ambulatory care setting. Study participants were asked to 'think aloud' as they used the CDMP. They were then debriefed at the completion of a 2-hour session, and a questionnaire was administered to them to collect qualitative data regarding their subjective impressions. The results of the study were used to identify opportunities for improving the system's usability. 
Progress to date

CDMP usability and impact on clinical workflow study.
This project examined the usability and impact on clinical workflow of the CDMP in the WRHCS. The project examined the CDMP's usability and impact on clinical workflow by comparing them to those of the existing, baseline health information system in the WRHCS. Specifically, we examined the Diabetes HealtheCard data (which documents the process and quality measures of the Diabetes Quality Improvement Program (DQIP)) of selected diabetes health care providers and administer questionnaires regarding aspects of the diabetes care system before and after adoption of the CDMP. In addition, we evaluated the use of the CDMP by observing the interactions of these care providers with standardized patients (i.e., actors who have been trained to provide a realistic initial or follow-up history for a simulated patent). Finally, we will use structured focus group discussions with the providers lead by a trained, experienced facilitator. Health care providers selected for this study were the Nurse Practitioners (NPs) of the Diabetes Institute of the WRHCS.
Progress to date:
The data collection portion of this study is complete and we have drafted a full report. The report will provide the basis for further modifications to the CDMP. At this time, we do not expect to submit the study results for publication.
Prospective clinical outcomes efficacy and cost efficiency study using the CDMP (Internet-based Diabetes Education and Case Management).
We will examine the efficacy and cost-effectiveness of two methods of diabetes education and care management --a traditional model that involves face-to-face encounters and telephone contact and an Internet-based model using a diabetes care management web site. We will compare these interventions to a usual care control group that receives no education or care management but is provided with Internet access. This study employs a randomized, prospective, parallel group design involving patients with diabetes mellitus. Primary outcome measures include clinical data (e.g. HbA1c, blood pressure, quality of life questionnaires) and secondary outcome measures include economic data (e.g. costs of case management, medication usage, and number(s) of ER visits/hospitalizations during the study period). We will study 150 participants with elevated HbA1c (³ 8.5%). Over 12-months we will measure HbA1c, office BP, and scores on the Problem Areas in Diabetes (PAID) questionnaire and Center for Epidemiologic Studies Depression Scale (CES-D). Participants receiving usual care will receive a notebook computer and Internet access. Those assigned to Internet-based care management will receive a notebook computer, Internet access and will interact with a care manager through a diabetes education and care management web site. Those receiving traditional care management will interact with a care manager following a structured contact schedule. Both care management models will employ medication algorithms to improve glucose and BP control, with the secondary goal of also improving diabetes-related stress and depression. We will collect data on process measures and health care utilization in order to conduct exploratory analyses on the cost-effectiveness of these interventions.
Progress to date:
The project is fully enrolled (152 patients) and final participant evaluations have taken place. Data analyses are now in progress. This study will be completed under the new contract with
University of Hawaii
The potential impact resulting from this study is that care management programs that deliver specialized services to patients with poorly controlled diabetes mellitus may ultimately reduce the drain on resources from diabetes and its complications. An Internet-based care management model may prove to be more costeffective can be delivered directly to patients in their home. Such a clinical initiative that successfully improves compliance with clinical guidelines will improve the care of such high-risk patients.
Clinical validation of the Behavior Assessment Tool (BAT) developed for the CDMP application (including test-retest reliability and validity).
The Behavioral Assessment Tool (BAT) was developed as a stand-alone module within the CDMP. It is a screening questionnaire containing questions about psycho-social factors, nutrition, physical activity, alcohol and tobacco use, medications, general health, self-monitoring of blood glucose and economic factors. There are two studies associated with testing its reliability and validity --An Assessment of the Test-Retest Reliability of the CDMP BAT and An Assessment of the Validity of the CDMP BAT (See Table 1 ).
The reliability assessment is a multi-site observational study with two measurements per study subject taking place 2 to 4 weeks apart. The sites are: the VA Boston Healthcare System (n = 42), Joslin Diabetes Center (n = 43 -with the additional subject being approved by the IRBs), Walter Reed Army Medical Center (n = 42), and community health centers in Hawaii (n = 42). The study protocol involves recruiting English-speaking individuals who are 20+ years of age and have type 1 or 2 diabetes. Eligible and interested participants are administered the following: a) an Informed Consent; b) a test to assess executive/cognitive function; c) questions about their social-demographics; and d) the BAT. Two to four weeks later, participants are asked to complete the same procedures (excluding the Informed Consent and questions about social-demographics). In addition, the study reviews participants' medical records to obtain their most recent A1c measure, Body Mass Index (BMI), and blood pressure. This information might be examined to help explain any low correlations between BAT responses over time. The validity assessment is also a multi-site observational study. This study will examine two types of validity -concurrent and predictive. We will measure concurrent validity by examining how study subjects' responses to its questions correlate with a) their responses to similar questions in other questionnaires administered at the same time, b) recent self-report physical activity and food "logs", c) a cotinine test (to assess smoking status), and d) concurrent health-related factors obtained from their medical records, including current or recent hemoglobin A1c (A1c), current or recent Body Mass Index (BMI), current prescribed medications, and current health conditions. We will measure predictive validity by assessing how study subjects' responses to BAT questions correlate with their future healthrelated factors, namely health-related factors at six months and twelve months after the BAT administration completed at the beginning of the study as part of Objective 1. The health-related factors we will examine include: new A1c ; new BMI; adherence to recommended foot and eye exams in the intervening period; number of hospitalizations, number of hospital days, and number of emergency room visits in the intervening period; new medications; frequency of provider use and type of provider use in the intervening period; and new health conditions. We are recruiting 75 subjects from Joslin, 75 from Walter Reed, and 75 from the community health centers in Hawaii for this assessment.
Progress to date on
Progress to date on Validation: Joslin has completed recruitment and is conducting analyses. As of 10/25/07, 47 subjects have been recruited at Walter Reed. The health centers in Hawaii are initiating recruitment. This study will be completed under the new contract with University of Hawaii 
Deployment of JVN Telehealth CDMP application into the Department of Defense Electronic Medical Record
The overall objective of this study was to incorporate CDMP and related applications into the enterprise electronic medical record (AHLTA). We have three specific objectives: Objective 1 is to conduct a "proof-of-concept" study that will investigate the feasibility of integrating CDMP's Diabetes Assessment Tool Kit (DATK) into AHLTA. Objective 2 will evaluate multiple methods of viewing and integrating glucose meter data uploaded through CDMP's Diabetes Mellitus Everywhere (DME) into AHLTA. Once in the CDMP application database the glucose data can be viewed in either the presentation-rich webbased environment of CDMP or in a PureEdge form. We can then incorporate the data into an AHLTA encounter via standard cut-and-paste techniques from CDMP or through the use of PureEdge forms.
In the case of PureEdge forms, we will use the planned capabilities of the product to import data into ALHTA automatically. Objective 3 is to assess the reliability of the glucose data to provide accurate information when accessed on-line via DME versus a computer in the clinic using proprietary software.
Status:
• As noted above, 
Development of additional modules for the JVN Telehealth CDMP application
The objectives are to develop additional modules that are enhancements to the existing CDMP application. Additional modules will include a medication module, an outcomes and reporting module, an education scheduling and tracking tool, a knowledge assessment tool, a nutrition module, a patient portal module, integration of wireless home monitoring devices, and a primary care practitioner module.
Status: Joseph Humphry, MD, designed a module for incorporation into the CDMP for use by health care providers for recording and displaying patients' medications. Frederick Walsh developed a prototype of the module for review by members of the consortium. This is currently implemented into the CDMP application. Additionally the outcomes and reporting module, and enhanced education module, a nutrition module, the patient portal (DME), and integration of home monitoring devices have all been successfully implemented in the CDMP application. Additionally, we completed negotiations with the 2 laboratory systems in Hawaii 
Status:
The role investigators play at the Durham VAMC and the Duke University Medical Center in this protocol is study design and data analysis. This site was largely responsible for the study design and protocol development. In addition, the statistical support for this project resides at this site. Our site will be responsible for receipt of the data and data analysis. The health economist assigned to this project is at this site and will be responsible for the economic data output and results that are derived from this study.
The following goals have been achieved during the review period:
• • Project management plans. The study team has reviewed the protocol, data collection methods, data analysis plans, and data transmission methods. We have also discussed the web-based interface proposed for use as a means of data transmission. The Health Services Research and Development Service has experience and local expertise with the use of web-based interfaces for data collection and transmission. Once study enrollment commences and we begin to receive study data, the study team will schedule regular meetings to review the progress of the study. Study and data management will be conducted using the Standard Operating Procedures of the Durham VAMC Health Services Research and Development Service. This includes measures to protect the privacy and confidentiality of research data and personal health information.
The analytic plan is as described in the final IRB-approved study protocol. No changes to the protocol are anticipated. However, if any changes are necessary, the site researchers will work with the collaborating institutions to amend the protocol and seek IRB approval for the changes. Objectives: To compare the effectiveness and cost of using teleophthalmology (TO) versus routine eye exam (EE) for diagnosing diabetic retinopathy and macular edema.
Methods:
We conducted the analysis by developing a Markov model. A cohort of 50-year old diabetics entered the model in "good ocular health." In following one-year cycles they remained in this health state, developed proliferative diabetic retinopathy (PDR) or clinically significant macular edema (CSME), or died. If they developed PDR or CSME, they may receive treatment and regain good ocular health, develop blindness, remain alive with PDR or CSME, or die. The intervention subtrees differed by 1) the proportion of diabetic patients screened by EE (0.60-0.83); 2) TO image failure rate (26%); 3) the test characteristics of TO and EE; and 4) adherence to follow-up exam (0.87 for TO and 0.77 for EE).
We derived transition probabilities, intervention test characteristics, health state utilities, and annual cost of blindness from the literature. We derived intervention costs via micro-costing and treatment costs from Medicare reimbursement rates. We applied a 3% discount rate to future costs and effectiveness.
We conducted 10,000 iterations of second-order Monte Carlo simulation of the Markov model to generate results. We also conducted extensive one-way sensitivity analysis to determine which parameters drove the model and the threshold values at which the results could change.
Results:
The model estimated a lifetime expected cost of $620 (95% confidence interval (CI) $510-$732) for a patient receiving annual TO screening and $708 (95% CI $495-$968) for a patient receiving annual routine EE. TO patients accrued 9.0 QALYs (95% CI 8.6-9.4 QALYs) and routine EE patients also accrued 9.0 QALYs (95% CI 8.6-9.5). The model was sensitive to five model parameters: 1) EE time, 2) gradable image percentage, 3) proportion of population screened by EE and TO, 4) follow-up adherence rate, and 5) sensitivities of TO and EE.
Conclusion:
Teleophthalmology is potentially equivalent to routine eye exam for diagnosing PDR and CSME but can do so at lower cost per patient.
Impact Statement: Teleophthalmology may provide a cost effective solution for improving compliance with VA guidelines that call for annual eye screening for diabetic veterans.
Joslin Diabetes Center Research and Development Status Reports
The above section addressed the research components of this large collaborative effort. In the following section, we summarize key issues and milestones in the technology research and development.
Establish a centralized JVN Telehealth clinical coordination center to facilitate the proposed multicenter clinical trials. Telehealth Clinical study Coordination Center as a module of CDMP to Facilitate proposed clinical trials
The JVN Telehealth clinical coordination center is an integral part of JVN program moving forward in the future and will provide the critical capability of providing a variety of professional services that provide value added to the JVN program as it begins to undertake the proposed rigorous multicenter clinical studies. These services were designed through the clinical coordination center under the direction of Dr. Stephanie Fonda, Dr. Lloyd M. Aiello and Dr. Bursell and provide pathways for direction and testing of various clinical work flow models as well as coordination and facilitation of different JVN related multi-center clinical trials. The expertise and programs provided through the coordination center present a compelling value to the JVN participating sites. The services that were provided are outlined below: 1. Client training on all tools; capture of clinical feedback for software updates; modifications to JVN clinical workflow processes as desired by health professionals using the JVN system. 2. Support for clinical programs development, identifying site-specific program requirements, and clinical pathways and workflows 3. Support for reading center services, establishing and updating certification programs and courses, maintaining performance for image review and reporting services, scheduling timely quality assurance reviews, and providing ongoing consultation services 4. On-going clinical support through resource development, maintaining quality assurance, consultative services, and provision of pre/post-deployment periodic site visits 5. Provide continuing education, both on-site at the JVN Tele-Health Clinical Coordination Center and at remote sites through on site visits or video teleconferencing 6. Coordinate reading centers to provide ongoing certification and re-certification services, for image acquisition specialists, image review specialists, and remote reading centers 7. Coordinate all clinical study activities associated with the clinical coordination center and provide a centralized data repository for the different proposed clinical studies.
Status:
Development of the Study Manager Module in CDMP with the data base established to support storage of study data and the utilities required to access this data for analysis has been completed and code development for anonymization of data, secure messaging, HIPAA compliance, and centralized storage has been completed. The module has been implemented and is being used by clinical study coordinators at the participating sites conducting proposed clinical studies
Clinical validation of the JVN Eye Care computer algorithm for automation of detection of retinal lesions.
Determine the sensitivity and specificity and Receiver Operating Characteristics (ROC) of the performance of the algorithm for detecting retinal abnormalities from undilated eye JVN digital video retinal images compared to dilated eye ophthamological evaluation of retinal images from 35 mm retinal fundus photography.
Status:
The algorithm development has been completed and undergone validation testing. Status: This study has not been initiated as retinal prototype development was cancelled due to reduction in funding for 2003 to 2007. Some additional work has occurred but is a lower priority. Currently modifications to the prototype now allow full field retinal images to be acquired without portions of retina being occluded by reflections from the lens and cornea. A US patent has been granted for this technology (US Patent # 7,338,167). Examples of retinal images obtained by this prototype are shown below. Currently exploring partnership with a device manufacturer to develop some beta units that can be clinically tested. Images below are retinal images taken with the retinal imaging prototype Automation of the retinal image taking process using the JVN developed retinal imaging device. Development of scanning technology that will automate imaging and simultaneous stereo acquisition of different regions of the retina determined to be essential for accurate diagnosis of diabetic retinopathy.
Status: This component has not been initiated due to funding reductions in 2003 to 2007. Once the retinal imaging device can be produced we will conduct the necessary clinical validation study.
Software Application for 3-Dimensional Visualization of the Retina Optic Nerve Head Mapping from Stereo Pairs
In lieu of the above automation process we have been investigating utilization of image analysis techniques to provide three dimensional mappings of the retina. These would be of value to provide an indication of relative elevation in the macula as an indication of risk for macula edema a sight threatening process or development of optic disc changes potentially associated with the development of glaucoma.
The figures below illustrate the work completed in this area. 
Status:
The software development for the JVN image acquisition application has been completed. Below is a summary of work performed:
JVN IMAGER JVN 4.0 Imager is an image acquisition product for capturing retina images based on the previous product JVN V3.0 (IA). MegaVision's digital camera back has been integrated in JVN V4.0 Imager. We have completed the following new features and enhancements:
• Add MegaVision's RIC Digital Camera to the product • Allow to save original raw image data • Re-program the product with Microsoft.NET technology to eliminate the troublesome product architecture generated by an outsourcing company. With the new Microsoft.NET technology, the architecture and product reliability will be dramatically improved.
• Resolve defects reported from previous releases.
• Improve user interfaces and product performance.
• Improve Modality Work List search engine.
• Support the compatibility of existing image acquisition devices JVN SERVER JVN 4.0 Server, a subset of the CDMP server, is an image and information management server that provides permanent storage capabilities of ophthalmic image and related information. Its function is mainly to provide "on-demand" distribution of diagnostic images of ophthalmic photography and related clinical reports of diagnosis, and also to automate permanent storage with virtually unlimited storage capacity. It is a serviceprovider oriented server that will be normally located in Joslin Diabetes Center, or perhaps other centralized hospital/clinic locations, if necessary. Furthermore, it provides features that contribute to the enhanced workflow of ophthalmologists and other ophthalmologic clinicians. It also provides information management features to those administrators who perform daily clinical and technical supports. The JVN Server consists of two major components: JVN DICOM Server and JVN Reader that leverages CDMP data monitoring and reporting capabilities. We have completed following major features:
DICOM Server
DICOM exists as the universal glue to connect JVN Server with JVN Image Acquisition and potentially any external 3
rd Party DICOM Systems. This is the interface over which JVN Server will receive images, structure reports, and HIS scheduling events. DICOM is also used to transmit images and structure reports out to other systems, but only when the "On-Demand" interface is not applicable.
The "On-Demand" Interface is a proprietary interface for the transmission of the images and managing of the workflow related to those images. The "On-Demand" Interface allows studies to be locked to a particular user, and the status of the study to be altered accordingly. This interface also offers a faster mechanism for the transmission of images to the requesting viewing workstation.
• • Support Web-based clinical reporting functionality (see Reporter features)
• Support Web-based administrative reporting functionality for clinical services
• Support Web-based administrative functionality for technical services
• Support a proprietary interface to provide "On-Demand" style functionality to JVN Reader.
Reporter
• Support a server application integrated with the JVN Reader client application
• Support study worklist display and filtering
• Support the entry of clinical findings and other patient data
• Support algorithms for the determination of potential eye diagnoses and risks
• Support review and distribution of completed JVN study reports JVN READER JVN Reader V4.0 is a Microsoft Windows based application that leverages CDMP for its reporting and storage functionality. This application has been designed with a large number of features to meet the needs of ophthalmic photography image display and diagnosis. We have completed following major features:
• Worklist and Clinical Findings interfaces -will access JVN Reporter and provide end users with patient/study worklist, clinical findings templates, and clinical reports templates. By linking to JVN reporter and JVN DICOM server, the interfaces will also provide a mechanism to download patient study related images for further diagnosis.
• Diagnostic Display -Diagnostic image display is a major software component that consists of a set of standard image process tools and a set of advanced image process tools. Diagnostic images are displayed on a thumbnail monitor and primary viewport monitor. Diagnosis can be done through using the thumbnail display and primary display, combined with the image process and manipulation tools. Reader-Server collaboration engine -JVN Reader uses the engine to communicate with JVN server where the study images are physically stored. This engine will triangulate JVN Reporter-Sever-Reader three parties to make web HTTP linking, image downloading and event notifications.
Department of Defense Integration Requirement.
Because of the introduction of CHCS II in the WRAMC Network we have also initiated an effort to accelerate the development of the JVN diagnostic display work station such that the CDMP and JVN eye care are a single application that can be embedded directly into CHCS II. This effort involves the integration of JVN diagnostic display into the CDMP application. It requires the development of a DICOM viewer integrated as a module in CDMP and leverages all the reporting capabilities of CDMP to generate diagnostic findings, clinical, diagnosis and clinical performance reporting. Included in this design will also be the ability to provide assessments and diagnosis for general ophthalmology applications. The advantage here is that the whole application exists on an open architecture leveraging the web based technology used for CDMP and no longer requires reliance on Agfa as a third party vendor for the PACS system. This is a necessity as Agfa has been no responsive to our support requests over the past 18 months despite the fact that we have paid them $30,000 per year for support of our application. The Figure below illustrates the high level architecture for the proposed solution.
We have completed the functional requirements definition portion of the project, the technical design portion of the effort, the software coding and the testing and implementation. Proposed JVN -CDMP Architecture
CDMP Development
Overall, we have been able to capitalize on our original mission: Create a patient-centric diabetes treatment application that fills the gaps in standard disease management software and empowers patients to become good self-managers through timely, accurate information and solid, collaborative relationships with their care providers. Support those providers with a number of clinical decision support tools and embedded education.
We are fortunate to be working with our original development team, using a strict system development methodology, conscious of the need for quality and documentation.
To review, the CDMP is a two-part application developed for medical centers and clinics.
The first part of the application --the CDMP Core (the Provider Portal) --is a web-based, secure, onestop, customizable, non-proprietary clinical tool that considers the whole patient and embraces Wagner's components for patient-centered chronic care. CDMP's primary users are
• Care managers who facilitate interactions between patients • CareTeam (physicians, nurses, educators, exercise physiologists, nutritionists, and behavioral clinicians) • Providers without specialization in diabetes
The second part of the application --the Patient Portal (currently called DME) --is also web-based and secure. It is a set of tools for self-management and communication that provides:
• A current health profile that reflects CDMP data in patient language • The ability to upload, review, and share (with a designated provider) personal health data from one or more monitoring devices
•
Functionality Summary:
o Reporting Module -CDMP is establishing a set of standard reports to be embedded and, therefore, available to every user. The first group of reports will fulfill DQIP, HEDIS and other certification criteria. Later reports will encompass more patient, provider, and site performance. o Study Manager -Developed to aid performance reporting and outcomes, this application has generated much interest in the research and provider communities because it lays out the process of capturing that information in a series of successive steps. o Nutrition Module -Bi-level nutrition assessment tools, the first for diabetes generalists to assess patients for the amount of control they have over the food issues in their lives. The second assessment is for CDEs and nutritionists to assess more subtle financial, emotional and lifestyle issues while looking at food choices and control.
We have begun the process of folding into the module an application that analyzes the selected components of foods and, with a nutrition profile of a patient, evaluates the balance of the patient's meals and makes suggestions that include essential nutrients and foods.
o Patient Portal -DME Everywhere, our portal, is evolving with rigorous use by the VA. We have made significant changes in language level and visual clarity in the past six months. adjustments to self-management plan, resource information from their care team, non-urgent questions o CarePlan -Significantly updated dynamic care planning is done and adjusted with the patient. The plan addresses our three targets -physical wellness, lifestyle self-management, and psycho-social healthwhile considering the issues of provider time, data-entry redundancy and plain language. CarePlans are easily updated and created. o Survey Architecture -Our robust architecture has allowed us to add surveys of all types to the core application to assess for depression, willingness to work on problem areas, and education needs.
Training
With a growing user base and more and more requests for demos, we have developed both ˜ demo systems with scripts that take the user through the core application, DME and the newer assessments and ˜ training materials that familiarize new users first, with the basic features -Alerts and Reminders, the Patient Snapshot, the Risk Profile, and CarePlanning -then gradually add in nuance and greater detail that optimize the application.
CDMP Clinical Data Warehouse -CDMP was designed to collect and maintain large amounts of data and a structure able to ˜ de-identify that data, ˜ perform structured queries, ˜ provide studies support, and ˜ develop predictive models.
Expert Reviews
The CDMP and its behavioral survey tool, Understanding Your Diabetes, have undergone expert reviews from American Institutes for Research. It is currently undergoing usability tests with the same organization.
Our own semi-annual reviews with the development consortium have produced pragmatic and valuable insights leading to more depth in the tools and greater interest from potential users.
Other CDMP Modules and Studies
Developing new modules to expand the capabilities of the application, and working group meetings to confirm functionality and identify additional functional enhancements.
Module Development and validation of Learning Level Assessment and Readiness to Learn tools for the JVN Telehealth CDMP application
This effort was identified as the first phase in developing a tool for patient knowledge assessment in the CDMP. The CDMP identified learning level assessment and readiness to learn as critical capabilities for enhancement of the CDMP application. It was recognized that there were only a few studies that addressed these issues and that the ability to perform rigorous studies to assess learning levels was of high value for this program.
The only validated tool for learning level assessment is the Rapid Estimate of Adult Literacy in Medicine (REALM) (1). This tool was developed as a rapid screening device to assist physicians in identifying patients with limited reading skills and in estimating patient reading levels. The results from this study suggest that the use of REAL appears to be a practical instrument for estimating patient literacy in the arenas of primary care, patient education and medical research. Another study used the Wide Range Achievement Test (WRAT) for measuring reading ability and spelling (2). Study results found that the better the ability to read and spell the better the accuracy of recall for food intake.
The limited studies currently available that address this issue provide the rationale and value for the development of a Learning Level Assessment tool for the CDMP. Concomitant with learning level assessment there also needs to be the ability to assess the patient's readiness to learn. Clearly if the patient has no interest in learning then the level of learning ability will be of little value.
The CDMP working group will develop a learning assessment tool based on the current validated measures and the available expertise within this group in the behavioral sciences will provide a valuable tool for assessing the patient' willingness to learn. This effort will be unique and will provide a significant advance in diabetes behavior modification.
Upon completion of this tool, it will need to be validated in a study comparable to that designed for the BAT above.
Status: Development of the appropriate tools that meet the different user requirements have been completed.
Usability Study. The Usability study of the CDMP application has been completed and the results were presented at the recent American Telemedicine Association Conference in San Diego. A number of proposed modifications to CDMP were identified from this study and are enumerated below. All modification have been incorporated into the CDMP application. ii. This sort indicator should be displayed on initial page retrieval. b. Update Data Changed Message -"Press OK to discard changes and leave this page. Press
Cancel to stay on the current page." c. JVN Eye Diagram -add text "Click on R/L links or image list to see eye images" d. Graphs -on y-axis -rotate dates so they are easier to read -should be displayed horizontally. e. Clinical Data Listings (Labs, Medications, Procedures, Diagnoses) i. Add alphabet across top, clicking on letter filters list based on the letter selected.
ii. Have "all" option to return to base -have tool tip when user mouses over all to explain this.
Home Monitoring Module. This has involved developing a collaboarative partnership with iMetrikus
Partnership with iMetrikus. As the patient portal began to be used by more and more patients to track critical aspects of their health and upload their meter data, we began to see an increase in the time our technical team and Estenda Solutions spent interpreting data, and documenting and supervising operating procedures for a variety of glucose meters. In order to efficiently provide functionality for increasing numbers of physiological home monitoring devices CDMP development initiated a partnership with iMetrikus, who provide a large number of device adapters and a universal data interface to the CDMP data server, both allowed us to branch out to other disease states and types of devices and frees the technical development team to focus on other more critical CDMP development efforts.
iMetrikus currently supports some 30 devices -blood glucose, blood pressure, weight scales, and oximeters, with more in the pipeline every day. The MetrikLink adapters convert the data into a single format for delivery to the MediCompass hub. CDMP takes the data handoff directly. iMetrikus is currently working with us to support several devices types within the same clinical program.
Status:
The iMetrikus CDMP interface has been developed, tested, and implemented and we anticipate starting a proof of concept study involving 20 patients with our partners in the Indian Health Service using the iMetrikus solution for home monitoring of blood glucose, weight and blood pressure.
Nutrition Module. A CDMP working group has put together several basic tenets of meal planning and nutrition information for patients and providers and is now working to find supporting web-based materials available for online work and/or printing for handouts. The CDMP web-based education list now includes most of the vetted sites the working group found valuable. The working group is also looking to find a new way to present this information to patients with limited general and health literacy.
The Nutrition module to be used in conjunction with the 2 nutrition surveys developed for CDMP has been completed. Further the library of nutritional resources that can be used by care managers has been significantly expanded.
Medications Module.
Medications are an increasingly important topic in the discourse on patient safety and personal health records. The CDMP Consortium, therefore, has determined that it is necessary to develop a state-of-the-art medications module. Discussions on medications have led to several iterations for Consortium consideration. Questions were:
• Do we present both disease state-specific -diabetes, in this instance -meds related and general meds? • About off the shelf medications and supplements, should they be included?
• How much real estate is available for medication categories?
• How far back should the medications tracking go for presentation?
• If EMR doesn't include all meds, how are they added?
• If EMR doesn't include a pharmacy module, how to track filled scripts?
• How to consider medication or supplement self-reports?
Status: . This module has been completed and below is the screen illustrating the form for medication presentation in CDMP. under review, "The Relationship of Internet-based Care Management and Changes in Glycemic Control to Depressive Symptoms and Diabetes-Related Distress." Thus, the Consortium is deepening the mental assessment and decision-support tools within the CDMP. The goal of these tools will be to identify depression and giving providers guidelines to handle the outcome. How to refer, who are first line providers, etc. are clinic specific issues that affect workflow. As with the basic nutrition assessment tool, such tools will include a scoring script -"If this, then this." to facilitate mental health care deliveryoften a presence with patients already coping with diabetes, CHF, etc.
Status:
The work here was deemed low priority and discontinued because of funding reductions. However, the work here will continue under the contract with Hawaii and will specifically focus on issues the affect patient willingness to change with respect to lifestyle and behavior modifications
Training tools.
Our CDMP Usability work with AIR and direct work with CDMP users changed some of our approach to training CDMP users. Traditional training involves taking the user logically through the application and covers keystrokes and trouble shooting. 
CDMP Summit Summary.
The CDMP Consortium -comprised of Joslin, JVN TeleHealth, DOD, VA, IHS, CDC, CHCs, and specialized academic researchers -meets twice a year with the overall goal to share technical, clinical, and behavioral updates to the CDMP Core application, JVN imaging and reporting tool, the patient portal, survey tools, and the study management tool. Most of our members are part of ongoing studies and working groups. This meeting allows us to share research, and related software and hardware development coming out of our clinical and behavioral work. We call these meetings "Summits". 
Status:
The biannual summit meetings were discontinued due to funding reductions.
Eye Care Application Development at Joslin Diabetes Center
There have been 2 major drivers that have dictated the technical development of the JVN Eye Care component of this project as outlined below:
1. The requirement to integrate the JVN system into AHLTA required an acceleration of the integration of the JVN Eye Care application as a module of the CDMP application. The aim here was to provide a single application that encompassed all our development work both in eye care and diabetes care into a single application that was ready for integration into AHLTA. This critical step has been accomplished together with added functionality into JVN Eye Care with the release of the next generation of JVN software (JVN 4.0) 2. With emerging technology the current JVN eye care analog video cameras were no longer being produced which required a development effort to define the specifications for a digital non-mydriatic retinal fundus imaging camera that conformed to the JVN specifications for low light level imaging. The discovery process resulted in a partnership with MegaVision to develop the required retinal imaging camera (RIC)
Status:
Successfully implemented CDMP based new clinic finding and reporting engine, coupled with centralized data management system. The new CDMP reporting engine automates the process of reporting clinical diagnosis and findings. • Step 2. DICOM MWL Query
Step 3. DICOM Storage SCU (OP, XC, SR)
Step Step 6
Step 7. Load Images S t e p 9 . C l i n i c a l R e p o r t s
Step 8. Read Studies
Step Successfully accomplished MegaVision camera research. We made the breakthrough of discovering how to acquire digital non-mydriatic images under lower or limited flash light. This discovery helped to improve the quality of ophthalmology images in very significant way. Through the raw images acquired by MegaVision camera, we are able to render or re-render images in many different ways, and in preliminary testing ophthalmologists using the system have noted pathologies that were not evident using the older JVN eye care system. We are currently investigating additional methodologies to improve image quality from this camera system.
Successfully accomplished the research of image deconvolution. Many patient/studies have been tested through the prototype of deconvolution algorithm. The data has indicated that the deconvolved images can dramatically improve the image quality and make clinical significance of retinal images more predominant, especially for those studies captured through MegaVision camera. The Figures A to F below illustrate images obtained from the same patient using the same exposure settings using the older analog imaging camera, the new digital MegaVision imaging camera and application of the deconvolution algorithm on the egaVision images.
By implementing all above projects, the clinical program has been improved and progressed dramatically as well. Since the image quality has been improved, the image pattern recognition and lesion detection are more achievable, which in turn will automate the diagnostic process and treatment plans. For this purpose, we have started the research of artificial intelligence for implementing a self-learning engine and eventually creating automated clinical treatment plan. CDMP is comprised of five independent software systems that share a common integrated technical architecture. While each of the five components received enhancements over the period, the most significant modifications were made to the Clinical and tele-opthamology applications. In addition to the progress summarized in this section, Estenda Solutions played a critical role in the support of CDMP for the Usability Study described above as well as rapidly implementing some of the critical modifications identified from this study.
Figures Showing Retinal Image Comparisons using old analog retinal imaging video camera, new digital MegaVision retinal imaging camera and new Retinal Image deconvolution algorithm applied to
Routine maintenance and enhancement
During the reporting period the Estenda team developed two major versions of the software culminating in the now current version 5.0. Over 175 miscellaneous updates were made as the team addressed user feedback issues across the suite.
Ongoing research support
During this reporting period the Estenda technical team supported live clinical trials conducted at the Boston VA, Joslin Diabetes Center, Walter Reed Army medical center, and University of Hawaii. To accommodate various technology restrictions the team was able to implement CDMP's study management module on several unique platforms including dated laptop technology. The team provided significant study manger design consulting for 3 major WRAMC research projects. The team also assisted principal investigators with access, formatting and analysis of the resulting study data, including analysis for two posters presented at the ATA 2007 annual meeting.
Ongoing implementation support
Modules from the CDMP suite are currently installed at a variety of locations both as part and in addition sites collaborating on this grant. During the reporting period the technical team support installations at: Joslin Diabetes Center; the Boston VA; Walter Reed Army Medical Center; 4 Hawaii based community health centers.
Clinical application
The clinical application underwent significant revision when incorporating functional changes resulting from the independent CDMP usability study conducted by the American Institutes of Research (AIR). Changes were made to key areas such as patient and population alert filtering, care planning. Various findings from the AIR study are included below:
Positive Findings 1. Testers were enthusiastic about the layout of the application, the types of data available on the application's clinical pages, and the application's ability to share patient data among team members. 2. Testers were able to successfully complete tasks that required them to locate existing clinical data for a specific patient. 3. Testers found it easy to read and understand the patient-specific clinical pages. 4. Testers wanted and expected the ability to customize the CDMP for their own use. This is a positive finding as the application was designed for such customization. It will be customized at each site that uses it at the time of implementation. 5. Testers did not quickly grasp all concepts (i.e., the Care Plan, Alerts, Reminders and some CDMP-specific rating scales). Given testers received only a brief training, it remains to be determined whether full training in the application would increase speed of understanding.
Findings Suggesting Areas for Improvement 1. Testers' presuppositions about what the application could do were not always congruent with the application's functionality. This suggested concrete ways that we might refine the application and/or develop training materials. 2. Testers thought certain lists (such as "Action Items" for patients and care managers) were in not in intuitive order. 3. Testers thought that drop-down menus were not an appropriate tool for items where they wanted to make more than one choice. 4. Testers thought error messages should be easier to read. 5. Testers thought that items unique to the CDMP (e.g., ratings scales) should be explained clearly so that even long-time users of the application may interpret the information correctly.
New Implementations
Under separate funding the CDMP suite was installed at Lackland Air Force Base, The National Kidney Foundation, The Hawaii Liver Center, and Baystate Medical Center.
Major Application Changes
In addition to 175 plus user enhancements, three significant modules were added to CDMP during the reporting period: Risk Stratification, Home Monitoring and Tele-Opthalmolgy
The new Risk Stratification engine is an independent risk calculator that can be accessed by both CDMP and other applications. Based on a comprehensive stream of anonymized patient data the engine is able to return a detailed report on the patients risk for major diabetic complications such as Retinopathy, Neuropathy, etc. The engine was designed as an independent web service that can be used by any application capable of sending and receiving XML data. Within CDMP the risk stratification data collection form was highly optimized to layer both historical and real time intervention data on a single form and is capable of returning the detailed patient reporting with nearly instant performance.
The new home monitoring application integrates the MetriLink device which allows patient's to upload from a wide variety of home monitoring devices over a standard phone line. This solution not only greatly expanded CDMP's device coverage, but also allows patients with limited internet access to easily report monitoring data from home. Within CDMP providers are able to fully register and manage patient's on the home monitoring network as well as retrieve and review results.
During this period a new generation of the tele-opthalmology application was brought into production at both the Joslin Diabetes Center and the Walter Reed Healthcare System. The new application, which was nearly a year in development, greatly expands the performance, flexibility and maintainability of the network and provides a significantly improved user interface for image evaluation and reporting.
Tele-ophthalmology application (JVN Eye Care)
Significant progress was made to bring the existing tele-ophthalmology application onto the CDMP common platform that required a close collaborative effort between the Joslin technical team involved in expanding JVN eye care functionality and the CDMP Estenda team. This infrastructure consolidation had several benefits including: Improved usability and maintainability, reduced infrastructure cost, and ability to be integrated into major DoD facilities such as Walter Reed Army Medical Center and AHLTA.
The system's capabilities for remote retina analysis, diagnosis and treatment planning were significantly improved by the development of a comprehensive reading center workstation. These new workstations consist of four high resolution monitors that allow the image reader to simultaneously view patient data, record findings, select various images, manipulate images and simulate three-dimensional retinal images. By integrating the reading station on the CDMP platform, clinicians are now able to incorporate the patient's full medical history including systemic risk factors for the progression of Diabetic Retinopathy (such as hypertension and hyperlipidema) Clinical workflow and Quality Assurance is also greatly improved with the new application that uses CDMP's patient identification and clinical worklist components. The application supports the following clinical workflow. The imaging modality is notified of scheduled patients, this notification prepopulates the modality with all required demographic and medical history data. The imaging technician uses this information during the encounter to provide real time education and identify emergent conditions. After imaging the modality transmits the completed study directly to the CDMP server via the newly developed DICOM interface. By incorporating DICOM communications in the CDMP infrastructure the program saves over $30,000 in annual licensing fees and eliminates products from a software vendor with a poor support organization. The CDMP DICOM engine stores the study and presents it for evaluation on the reader's desktop. Once presented and selected from the reader's worklist all study related information is streamed to the reading workstation. The study is presented to the reader across four screens, the reader evaluates the image using a series of image review and manipulation tools (magnification, stereo, measurement, color manipulation, etc) the reader fully documents their findings in the system (including new image quality feedback). Once the findings are saved, the CDMP determines various ophthalmologic diagnoses using a set of algorithms (these algorithms were also enhanced during this reporting period to take full advantage of the new capabilities) The diagnoses are then presented to the reader for review, final comment and development of a patient specific treatment plan. After the user signs the study report it may be automatically emailed (via 128 bit encrypted .pdf file), faxed or electronically submitted back to the referring physician.
By moving the tele-opthalmolgy application to the CDMP platform the team was also able to incorporate a full Quality Assurance program into the software. During this reporting period the team developed both criteria and workflow for program quality assurance. They system is capable of both enforcing random, blinded peer-topeer and peer to supervisor quality assurance reviews, reading center to imaging station reviews as well as custom group comparisons. To further improve program quality and reader productivity any reader may automatically request a supervisor or peer consult on a given study at any time during the reading process.
Key Research Accomplishments
• Development of study design and protocols for the proposed multicenter clinical studies
• Refinement of the automated retinal image analysis algorithm to improve sensitivity and specificity for detecting microaneurisms • Retinal imaging prototype is now acquiring good quality retinal images 
Conclusions
The study design for the proposed multicenter prospective clinical trials have been completed, have received approval though participating organization human subjects review boards, and have been approved through HSRRB. The proposed studies are in various stages of initiation, recruitment, or completion. For completed studies data has been analyzed and manuscripts are being prepared for submission. These prospective studies are important as they are designed to demonstrate both clinical efficacy and cost effectiveness of the JVN program. If the hypothesis of clinical efficacy and cost effectiveness are born out by the results from these trials then the broad introduction of this application into the health care system will be facilitated and could result in significant health care dollar savings associated with the care of patients with diabetes.
The Comprehensive Diabetes Management Program (CDMP) application has undergone a number of versions and we have developed significant new functionality to the application. The CDMP architecture was key in the seamless integration of the JVN eye care program as a module of the CDMP application. The integration of JVN eye care into CDMP was a critical step to complete integration of a single application into AHLTA.
The JVN Eye care module has also undergone significant revision that incorporates increased reporting functionality for both diabetic retinopathy and other non-diabetes related eye diseases such as age related macula degeneration. The reporting functionality also leverages CDMP risk assessment so that a clinical plan for appropriate eye care also takes into account systemic risk factors that may increase the progression of diabetic retinopathy. Additionally, because analog video cameras, are no longer available we have had to research digital video cameras that can be used to meet the requirements for low light level retinal imaging without pupil dilation. This research has been completed in partnership with MegaVision where we have developed a digital camera with superior imaging capabilities that continues to meet JVN requirements for low light level imaging. This camera is currently undergoing rigorous clinical validation for diagnostic accuracy.
With the completion of the CDMP patient portal (Diabetes Management Everywhere (DME) and its utilization in a prospective clinical trial we have worked on expanding DME functionality to support a broader range of home monitoring devices. In order to accomplish this we have established a partnership with iMetrikus who have developed a universal adaptor that allows communication between multiple devices through DME to the CDMP server. The DME portal facilitates secure communication between patient and provider with respect to downloaded patient information such as weight, blood pressure, and blood glucose monitoring values. The system also allows patients to down load digital images for review by care managers, for example patients can down load images of their meals for discussion regarding portion size and calories with nutritionists.
Furthermore, the clinical studies currently proposed and underway in this contract will be completed as part of the new contract with University of Hawaii. As part of this effort we will continue with Estenda to provide continued support and maintenance of the CDMP application for all sites. Additionally Estenda will work with investigators to implement new functionality as the reduced funding permits. The completion of the JVN eye care component of the proposed work will now be performed under a subcontract from the University of Hawaii to the Joslin Diabetes Center. • The University of Texas Health Science Center, San Antonio. TX: 1000 by 1000
• Apply image illumination correction and contrast enhancement
• Calculate image quality (IQ) metrics to characterize each image Entropy -Spatial Freque ncy Contrast -etc.
• Evaluate the effects of image proce ssing for contrast enhancement
• Assess Image quality effects on automatic lesion detection (microaneurysm segmentation) using Joslin Vision Network images: 480 by 640, non-mydriatic. stereo images with 45 degree field of view and collect ed non-mydriatically. 97 subjects (74 with no DR and 23 with not DR) were included.
Image Quality Metrics were calculated for Image types/ modalities:
Contrast= ~n~ ~~p(i, j} The computer-based digital retinal photo screening system screens low quality Images basad on Image quality metrlcs prior to the automatk ~of MAs.
Uneven lighting Is common to most retinal Images. especially when Dlumlnatecl
non·mydrlatlcally. An Image flattening process Is applied t o , _ the uneven Illumination.
The MAs were segmented using a top-hat transformation (2[. Two data sets were used In the study:
The higher resolution Images -re 1400 by 1200 pixels with 30 degree field of view and collected through pharmacaloclally dilated pupils. 10 patients with DR and 8 without DR -relncluded.
Joslin Vision Network Images
High resolution fundus Images -A clinical sensitivity of 90% and a specificity of 87.5% -re achieved. The dataset Is very small and no validation was performed on an Independent data sat.
Low resolution fundus Images
-A clinical sensitivity of 69% and a specificity of 68% _,. achieved for the training data. -A clinical sensitivity of 83% and a specificity of 69% -reachieved for the test data. -Image pre-processing Improved sensitivity and specificity to 92% and 74% respectively -The positive predidive value was found to be greater than the prevale nce of both the training and t esting sets This project demonstrated that Image quality through Image enhancement techniques can add significantly to the detection of lesions through automated means or in the visualization by readers.
To assess t he Impact of Image qua lity on the effectiveness of detecting dia betic retinopathy (OR) lesions in retinal images.
Background
Today's tele medicine systems are constrained by economics a nd communications capa bilities.
Intuitively, bener lrn.ge quality through finer pixel repre .. ntation of a rn.dical image ohould Im prove the " noitivity and opecificity with which a hunYin gruter or a computer·based algorithm can detect lesions auoclated with OR.
Oeclolonoto upgrade to "high-end"lrn.glng technologies that may unnec unnecesoarlly add to the co" of the medical service and will require additional bandwidth muot be aoseosed in terms of their value added.
Clinical significance Is often not thoroughly evaluated or Ignored.
,.,, 1tChnolouto lmprwe Image quality at little or no added cost is required fora nullllllr -..llatlonslft the hNithcare system. Including remote _..... Mdcllnlcal Httlng -lng and dlnkal setting.
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• Computer-based MA Segme ntation:
The computer·based digital retinal photo screoenlng system first ldentlflts autorn.tically those digital fundus lrn.ges of sufflcJ.nt quality for the IIUtotnllllc sagmentation of MAs based on l1111111e quality metria.
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Two data sets we re used in the study:
The higher resolution Images were 1400 by 1200 pixels with 30 dagree field of view and collected through pharmacalocially dilated pupils. 10 petlenll with DR and 8 without DR were Included.
JVNOata
High resolution fundus images · A clinical sensitivity of 90% and a specificity of 87.5% were achieved. The dataset is very small and no validation was performed Oft an Independent dataset.
Low resolution fundus images
· A clinical sensitivity of 83% ond a specificity of 69% were achieved for the training data. · A clinical sensitivity of 83% and a specificity of 69% were achieved for the test data. · Image preprocessors improved sensitivity ond specificity to 92% ond 74% respectively · The positive predictive value was found to be greater than the preva lence for both thetralnlnt and testing sets This project demonstrated thot Image quality through Image enhancement techniques can odd significantly to the sensitivity ond specificity of scrH nlng for DR in at risk patients without Increase bandwidth require ments, and with llnle added cost.
ease management by telemedicine and telehealth. There are an estimated 2 1 million Americans with DM a nd more than 150 million people worldwide with the condition, with the number of cases increasing at epidemic rates . .,. DM is a complex, chronic disease ~hat requires lifelong care. Everyone with DM is at risk of developing DR, which is a well characterized, sight-threatening microvascular complication ofDM ;'o," there are solid, evidence-based clinical management strategies established over the last 35 years that are effective in preserving vision; DR is frequently aS}~npto matic in its most treatable stages; the prevalence and incidence of DM, with its acc.ompanying complications, are g rowing at alarming rates worldwide; and many persons with DM do not receive regular eye care a nd sight-preserving treatments, even when such care and treatments may be readily available. DM poses sig nificant personal and societal problems, remaining a leading cause of vision Joss in industrialized countries . M ultiple nationwide clinical trials, including the Diabetic Retinopathy Study, u the Early Treatment Diabetic Retinopathy Study (ETDRS),"·" the Diabetes Control and Complications Trial," and the United Kingdom Prospective Diabetes Study," have demonstrated effective care and treatment programs for DR, but because many individuals who would benefit from sight-preserving care do not receive this care, DM is a significant cause of preventable vision Joss a ncil blindness worldwide.'' While telemedicine has the potential to extend sightpreserving diabetes eye care, it is crucial that telemedicine programs match the qualitty of care expected in traditional clinical settings. Because there are evidenced-based methods to preserve vision for those with DM faced with an increased risk of vision Joss, ocular telemedicine should include a nd apply these proven methods. The ATA, recognizing the importance of evidence-based care in telemedicine, established consensus recommendations for ocular CONTINUGD ON PAGG 5 6 The majority of the sample was female, white, and had type 2 diabetes (70%, 84%, and 70% respectively). The average age of the subjects was 61 ± 13 years. Eighty-eight percent of the subjects completed the study; dropouts were not significantly different demographically from completed subjects. Table 2 list the demographics of the population for this study, i.e. age group, gender, race/ethnicity, education, diabetes type, and income.
Overall test-retest reliability ranged from -0.06 to 1.0 with seventy percent of all BAT questions having an acceptable test-retest reliability (r ? 0.50). Among the BAT questions being compared against other reliable questionnaires the overall test-retest reliability ranged from 0.27 to 0.98 with eighty percent of the BAT questions having an acceptable test-retest reliability. Table 3 list all of the percent agreements and Spearman rank coefficient or Cramér's V with p-values for the BAT questionnaire questions.
For most BAT questions, test-retest reliability is acceptable and suitable for clinical use (r ? 0.50). However, it is lower for the questions "eat3meals" (r = 0.37), "missmeds" (r = 0.27), "checkfeet" (r = 0.42), "vision" (r = 0.29), and "probpayfood" (r = 0.37).
Further study is required to determine: a) whether the low reliability is specific to this sample; and b) possible reasons for the low reliability scores, such as question wording. Data collected from other sites might shed light on the first issue, and ongoing studies of the BAT's validity may address the issue of question wording.
Recruitment for study subjects occurred at Joslin Diabetes Center (Boston), a tertiary care specialty hospital. Subjects were considered eligible if they had diabetes for 2 years or more, were 18 years old or older, and comfortable speaking and reading English. 
